AuditLine › HHS OIG › Centers for Medicare and Medicaid Services
HHS OIG recommendation 22-E-BL-027.01
CMS should encourage Part D plans to increase access to and use of the authorized generic versions of Epclusa and Harvoni, within the authorities…
The recommendation, in the publisher's words
CMS should encourage Part D plans to increase access to and use of the authorized generic versions of Epclusa and Harvoni, within the authorities granted under statute.
- Responsible agency
- Centers for Medicare and Medicaid Services
- Issued
- August 9, 2022
- Report
- Part D Plan Preference for Higher-Cost Hepatitis C Drugs Led to Higher Medicare and Beneficiary Spending (OEI-BL-21-00200) · find it at HHS OIG
- Kind of report
- Evaluation
- Agency response
- Concur (as recorded by the publisher)
- Last update received
- October 26, 2026
- Next update expected
- December 16, 2026 (publisher's date)
- Publisher topics
- Financial Stewardship, Prescription Drug
“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.
Dated history
- Issued by HHS OIG. (publisher's date)
- First recorded by AuditLine. (start of AuditLine's own history for this record)
Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.
Other recommendations from this report
1 more, of which 0 are open in the publisher's file.
- CMS should pursue additional strategies�such as educating providers and pharmacies�to increase access to and use of lower-cost hepatitis C drugs in Medicare Part D.HHS OIG 22-E-BL-027.02 · issued Aug 9, 2022 · closed Dec 16, 2025Closed Implemented
Source
Open this report in HHS OIG's tracker This publisher's records (CSV)
Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows,
SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.